This article is more than 5 years old. Information may no longer be current.
Peramivir safe and effective for treating uncomplicated influenza
A single intravenous dose of peramivir may be a viable alternative to an oral 10-dose oseltamivir regimen for treating patients with uncomplicated acute influenza.
Findings from a double-blind phase 3 trial indicated that median time to symptom alleviation was reduced in patients assigned to either a 300 mg or 600 mg dose of intravenous peramivir compared with patients assigned to oseltamivir.
Researchers from several sites in Korea, Taiwan and Japan randomly assigned 1,091 patients who tested positive for influenza using rapid antigen detection to receive either one IV dose of peramivir (300 mg, n=364; 600 mg, n=362) or 75 mg of oseltamivir orally for five days (n=365). Median times to symptom alleviation were as follows:
- Peramivir 300 mg; 78 hours.
- Peramivir 600 mg; 81 hours.
- Oseltamivir; 81.8 hours.
Additionally, significantly lower adverse drug reactions were observed in patients assigned to 300 mg peramivir compared with those assigned to oseltamivir. – by Nicole Blazek
For more information: